|
Product analysis: no product was returned.Conclusion: without the return of the product, no definitive conclusion can be made regarding the clinical observation.Medtronic is submitting this report to comply with fda reporting regulations under 21 cfr parts 4 and 803.This report is based upon information obtained by medtronic, which the company may not have been able to fully investigate or verify prior to the date the report was required by the fda.Medtronic has made reasonable efforts to obtain more complete information and has provided as much relevant information as is available to the company as of the submission date of this report.This report does not constitute an admission or a conclusion by fda, medtronic, or its employees that the device, medtronic, or its employee caused or contributed to the event described in the report.In particular, this report does not constitute an admission by anyone that the product described in this report has any ¿defects¿ or has ¿malfunctioned¿.These words are included in the fda 3500a form and are fixed items for selection created by the fda to categorize the type of event solely for the purpose of regulatory reporting.Medtronic objects to the use of these words and others like them because of the lack of definition and the connotations implied by these terms.This statement should be included with any information or report disclosed to the public under the freedom of information act.A good faith effort will be made to obtain the applicable information relevant to the report.If information is provided in the future, a supplemental report will be issued.
|
|
Medtronic received information that 6 years and 7 months post implant of this 12mm pulmonary valved conduit in a 1 year 4 month old pediatric patient, it was explanted and replaced with a 18mm conduit of the same model.The reason for replacement was reported as conduit insufficiency.It was reported that aneurysmal dilation and the appearance of a pseudoaneurysm were noted at the distal end of the conduit, which was found to be likely secondary to outflow obstruction due to the patients history of hypoplastic pulmonary arteries.It was also reported that a proximal left and right pulmonary arterioplasty was performed during this procedure.Lastly, it was reported that postoperative bleeding was noted which required three rounds of platelets, cryoprecipitate and two doses of novoseven recombinant- factor vii.A post-repair intraoperative transesophageal echocardiogram showed no significant right ventricle ( rv) to pulmonary artery (pa) conduit dysfunction or stenosis.No additional adverse patient effects were reported.
|